Wüsthoff, Linda Elise Couëssurel
Lund-Johansen, Fridtjof
Henriksen, Kathleen
Wildendahl, Gull
Jacobsen, Jon-Aksel
Gomes, Leni
Anjum, Hina Sarwar
Barlinn, Regine
Kran, Anne-Marte Bakken
Munthe, Ludvig Andre
Vaage, John T.
Funding for this research was provided by:
University of Oslo
Article History
Received: 16 May 2023
Accepted: 14 May 2024
First Online: 19 June 2024
Declarations
:
: The study has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans []. Participants were recruited on basis of informed and written consent. The size of the monetary incentive (10–20 euros) is not considered to be of a size that would compromise the consent procedure. This study was approved by the Norwegian Regional Ethics Committee (approval no 166545) and the Data Protection Officer at Oslo municipality.The COVID-19 study and biobank at Oslo University Hospital was approved by the Norwegian Regional Ethics Committee with approval number 135924. The Norwegian Coronavirus study, the Mother and Child study, the NorFlu study and health care workers were approved by the Norwegian Regional Ethics Committee with approval numbers 124170, 127798, 18403, and 235424, respectively. The cohort study on vaccinated patients treated with anti-CD20 antibodies for Multiple Sclerosis [] was approved by the Norwegian Regional Ethics Committee with approval number 229747.Participants received immediate access to their SARS-CoV-2 test results, and treatment and preventive measures were continuously implemented in accordance with the clinical guidelines applicable at the time.
: Not applicable.
: Fridtjof Lund-Johansen has received a grant from CEPI (Coalition for epidemic preparedness and Innovation) for 2021-2024, and from the South East Regional Health Authorities in Norway in 2020. Both Grants were paid to the institution. None of the other authors have any competing interests to declare.